Analysts say head-to-head study results could make Kyprolis the lead treatment.
Drugmakers face increasing pressure on pricing from insurers and PBMs.
The breakthrough designation therapy drug was the first for its drug class.
Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.
Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.
Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.
The organization plans to publish a scientific and a lay abstract detailing study findings
Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.
Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.
A report by the New York Times, citing a lack of an advisory committee for Vyvanse and illegal marketing lawsuits resolved last year, expressed concerns that the drug for binge-eating disorder will be overprescribed.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Poll shows all ages seek digital health tools
- Survey shows docs overestimate adherence
- Drugmaker shifts sales model to keep pace with formulary decision making
- Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence
- Global cancer drug market to grow to $111 billion by 2020: report